These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1391 related articles for article (PubMed ID: 18083065)
1. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G; Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065 [TBL] [Abstract][Full Text] [Related]
2. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148 [TBL] [Abstract][Full Text] [Related]
3. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061 [TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725 [TBL] [Abstract][Full Text] [Related]
5. Update of the BIG 1-98 Trial: where do we stand? Joerger M; Thürlimann B Breast; 2009 Oct; 18 Suppl 3():S78-82. PubMed ID: 19914548 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL; J Clin Oncol; 2007 May; 25(15):2006-11. PubMed ID: 17452676 [TBL] [Abstract][Full Text] [Related]
7. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial. Forbes JF Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270 [TBL] [Abstract][Full Text] [Related]
8. Understanding the BIG results: Insights from the BIG 1-98 trial analyses. Wardley AM Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768 [TBL] [Abstract][Full Text] [Related]
9. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. Jahanzeb M Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537 [TBL] [Abstract][Full Text] [Related]
10. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957 [TBL] [Abstract][Full Text] [Related]
11. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Forbes JF; Sestak I; Howell A; Bonanni B; Bundred N; Levy C; von Minckwitz G; Eiermann W; Neven P; Stierer M; Holcombe C; Coleman RE; Jones L; Ellis I; Cuzick J; Lancet; 2016 Feb; 387(10021):866-73. PubMed ID: 26686313 [TBL] [Abstract][Full Text] [Related]
12. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. ; Mouridsen H; Giobbie-Hurder A; Goldhirsch A; Thürlimann B; Paridaens R; Smith I; Mauriac L; Forbes J; Price KN; Regan MM; Gelber RD; Coates AS N Engl J Med; 2009 Aug; 361(8):766-76. PubMed ID: 19692688 [TBL] [Abstract][Full Text] [Related]
13. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ; Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631 [TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B; Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287 [TBL] [Abstract][Full Text] [Related]
16. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902 [TBL] [Abstract][Full Text] [Related]
17. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Ingle JN; Tu D; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Goss PE Breast Cancer Res Treat; 2006 Oct; 99(3):295-300. PubMed ID: 16541302 [TBL] [Abstract][Full Text] [Related]
18. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T; Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060 [TBL] [Abstract][Full Text] [Related]
19. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J; Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253 [TBL] [Abstract][Full Text] [Related]
20. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]